Royalty PharmaMEX:RPRXN 72 Pretax Margin % is 74.26% as of Mar. 2026, which is 3% above its 10-year median of 72.20. GuruFocus rates MEX:RPRXN with a GF Score™ of 72/100 and a GF Value™ of MXN535.17. The stock has 10 warning signs investors should review. Among 947 Biotechnology companies, Royalty Pharma ranks better than 96.2% on this metric.
Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. Royalty Pharma's Pre-Tax Income for the
three
months ended in Mar. 2026 was MXN8,444 Mil. Royalty Pharma's Revenue for the
three
months ended in Mar. 2026 was MXN11,371 Mil. Therefore, Royalty Pharma's pretax margin for the quarter that ended in Mar. 2026 was 74.26%.
The historical rank and industry rank for Royalty Pharma's Pretax Margin % or its related term are showing as below:
MEX:RPRXN'
s Pretax Margin % Range Over the Past 10 Years
Min: 10.28 Med: 72.2 Max: 135.67
Current: 55.69
MEX:RPRXN's Pretax Margin % is ranked better than 96.2% of 947
companies
in the Biotechnology industry
Industry Median: -90.63
vs MEX:RPRXN: 55.69
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
Royalty Pharma Pretax Margin % Related Terms
Royalty Pharma Pretax Margin % Historical Data
* Premium members only.
The historical data trend for Royalty Pharma's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:RPRXN vs BNTX, INSM, ROIV: Pretax Margin % Comparison
For the Biotechnology subindustry, Royalty Pharma's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Royalty Pharma Pretax Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Royalty Pharma's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where Royalty Pharma's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Royalty Pharma (MEX:RPRXN) has a Pretax Margin % of 74.26% as of Mar. 2026. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Royalty Pharma and its competitors. This is near median its historical median of 72.20. Over the past decade, Royalty Pharma's Pretax Margin % has ranged from 10.28 to 135.67. According to the industry distribution chart, Royalty Pharma ranks #36 out of 947 companies in the Biotechnology industry, placing it in the top 3.8%.
Is Royalty Pharma's Pretax Margin % too high?
Royalty Pharma's current Pretax Margin % of 74.26% is near median its 10-year median of 72.20. Over the past 10 years, this metric has ranged from a low of 10.28 to a high of 135.67. Based on the distribution chart, Royalty Pharma ranks #36 out of 947 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Royalty Pharma has a GF Score™ of 72/100, reflecting its overall financial health beyond just this single metric.
How does Royalty Pharma's Pretax Margin % compare to BNTX and INSM?
According to the Biotechnology industry distribution chart, Royalty Pharma ranks #36 out of 947 companies for Pretax Margin %. This places Royalty Pharma in the top 4% of its industry — outperforming the majority of peers. Historically, Royalty Pharma's own Pretax Margin % has ranged from 10.28 to 135.67 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Biotechnology company?
A good Pretax Margin % depends on the Biotechnology industry context. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Royalty Pharma and its competitors. Royalty Pharma's current Pretax Margin % is 74.26%, which is near median its own 10-year median of 72.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Royalty Pharma stock overvalued right now?
Royalty Pharma (MEX:RPRXN) has a current Pretax Margin % of 74.26%. The stock's GF Value™ is MXN535.17, compared to a current price of MXN775.06 — trading 44.8% above its estimated fair value. The current Pretax Margin % is 74.26%, which is near median its 10-year median of 72.20. Royalty Pharma's overall GF Score™ is 72/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Royalty Pharma (MEX:RPRXN), the current Pretax Margin % is 74.26% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Royalty Pharma (MEX:RPRXN) Overvalued in 2026?
Based on GuruFocus' analysis, Royalty Pharma stock appears to be overvalued.
The current stock price of MXN775.06 is trading 44.8% above its estimated GF Value™ of MXN535.17.
Key valuation signals for MEX:RPRXN:
Pretax Margin %: 74.26% (near median its 10-year median of 72.20)
GF Value™: MXN535.17 vs. price of MXN775.06 (44.8% above fair value)
No single metric tells the full story. See the MEX:RPRXN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
72GF Score
Get the complete analysis for MEX:RPRXN
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:RPRXN has been successfully added to your 
